ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,773,721 | +623.6% | 133,096 | +731.6% | 0.00% | – |
| Q2 2023 | $383,296 | -16.7% | 16,004 | -50.9% | 0.00% | – |
| Q2 2022 | $460,000 | -57.0% | 32,619 | -26.2% | 0.00% | -100.0% |
| Q1 2022 | $1,071,000 | +1.7% | 44,228 | -2.0% | 0.00% | 0.0% |
| Q4 2021 | $1,053,000 | -83.6% | 45,108 | -81.8% | 0.00% | -80.0% |
| Q1 2021 | $6,411,000 | -90.1% | 248,505 | -79.4% | 0.01% | -90.0% |
| Q4 2020 | $64,637,000 | +29.9% | 1,209,077 | +0.3% | 0.05% | +13.6% |
| Q3 2020 | $49,741,000 | -6.6% | 1,205,846 | +9.8% | 0.04% | -12.0% |
| Q2 2020 | $53,237,000 | +35.9% | 1,098,345 | +18.4% | 0.05% | +6.4% |
| Q1 2020 | $39,184,000 | +306.6% | 927,435 | +311.7% | 0.05% | +422.2% |
| Q4 2019 | $9,636,000 | +71.5% | 225,247 | +44.3% | 0.01% | +50.0% |
| Q3 2019 | $5,620,000 | +83.0% | 156,147 | +5.5% | 0.01% | +100.0% |
| Q3 2018 | $3,071,000 | +35.2% | 147,949 | -0.5% | 0.00% | +50.0% |
| Q2 2018 | $2,271,000 | +235.9% | 148,748 | +728.7% | 0.00% | +100.0% |
| Q3 2017 | $676,000 | +43.5% | 17,950 | +6.4% | 0.00% | – |
| Q2 2017 | $471,000 | -18.8% | 16,873 | 0.0% | 0.00% | -100.0% |
| Q1 2017 | $580,000 | +51.4% | 16,873 | +27.2% | 0.00% | – |
| Q4 2016 | $383,000 | +15.0% | 13,263 | +26.7% | 0.00% | – |
| Q3 2016 | $333,000 | -2.1% | 10,468 | 0.0% | 0.00% | – |
| Q2 2016 | $340,000 | -85.7% | 10,468 | -87.7% | 0.00% | -100.0% |
| Q1 2016 | $2,374,000 | -22.0% | 84,903 | -0.5% | 0.00% | -25.0% |
| Q4 2015 | $3,043,000 | +27.4% | 85,356 | +18.2% | 0.00% | +33.3% |
| Q3 2015 | $2,388,000 | +56.8% | 72,204 | +98.5% | 0.00% | +50.0% |
| Q2 2015 | $1,523,000 | -22.4% | 36,371 | -39.6% | 0.00% | 0.0% |
| Q1 2015 | $1,962,000 | -6.6% | 60,201 | -9.0% | 0.00% | 0.0% |
| Q4 2014 | $2,101,000 | +24.8% | 66,160 | -2.8% | 0.00% | 0.0% |
| Q3 2014 | $1,684,000 | +3.9% | 68,031 | -5.2% | 0.00% | 0.0% |
| Q2 2014 | $1,621,000 | +16.5% | 71,750 | +25.4% | 0.00% | 0.0% |
| Q1 2014 | $1,392,000 | -6.2% | 57,220 | -3.6% | 0.00% | 0.0% |
| Q4 2013 | $1,484,000 | -9.3% | 59,370 | -0.4% | 0.00% | 0.0% |
| Q3 2013 | $1,637,000 | +59.4% | 59,610 | +6.9% | 0.00% | +100.0% |
| Q2 2013 | $1,027,000 | – | 55,740 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |